BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:http://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20240101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250429
DTEND;VALUE=DATE:20250502
DTSTAMP:20260515T094043
CREATED:20250204T091737Z
LAST-MODIFIED:20250204T091823Z
UID:40418-1745884800-1746143999@www.pharmajournalist.com
SUMMARY:2nd Measuring Patient Engagement Summit
DESCRIPTION:As the healthcare industry evolves\, patient engagement has become a crucial factor in shaping clinical trials\, accelerating regulatory approvals\, and improving the overall patient experience. \nYet\, amidst a challenging funding environment\, empowered patients rightfully demanding greater involvement in treatment decisions\, and regulatory bodies requiring transparent reporting of patient engagement activities\, it has become more critical than ever to establish quantitative measures for assessing the impact of these initiatives. \nThe 2nd Annual Measuring Patient Engagement Summit 2025 is the premier event dedicated to addressing this challenge. Bringing together top experts from Patient Engagement\, Advocacy\, Affairs\, Experience\, Insights\, and Marketing\, this summit offers a platform for thought leaders to share data-driven strategies and actionable insights. Attendees will explore innovative case studies that showcase how patient engagement initiatives can be effectively measured\, ensuring they deliver real impact while meeting compliance and ROI expectations. \nKey topics will include: \n\nEstablishing standardized metrics for patient engagement success\nAligning patient engagement strategies with regulatory expectations\nDemonstrating ROI to internal and external stakeholders\nLeveraging patient insights to improve trial design and healthcare outcomes\n\nBy uniting industry leaders to develop a consistent framework for measuring patient engagement\, this event ensures that patient-centered innovation remains at the forefront of healthcare transformation. \nJoin us to drive measurable\, meaningful progress in patient engagement — because when we quantify what matters\, we create a healthcare system that works for everyone. \nTo know more visit: www.measuring-patient-engagement-summit.com
URL:http://www.pharmajournalist.com/event/2nd-measuring-patient-engagement-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250429
DTEND;VALUE=DATE:20250502
DTSTAMP:20260515T094043
CREATED:20250317T140929Z
LAST-MODIFIED:20250317T140929Z
UID:40719-1745884800-1746143999@www.pharmajournalist.com
SUMMARY:2nd GLP-1-Based Therapeutics Summit
DESCRIPTION:The 2nd GLP-1-Based Therapeutics Summit is an exclusive gateway to competitive intelligence into the continued potential of cutting-edge GLP-1s for obesity\, weight loss\, diabetes\, and beyond. Join us to hear the latest clinical data on combination therapies to enhance muscle preservation\, indication expansion into new areas\, and strategies to improve the efficacy\, tolerability\, and durability of GLP-1s. With these drugs continuing to dominate the headlines\, there is no better time to unite with 100+ C-level executives\, decision-makers\, and scientists at the forefront of the rapidly evolving world of GLP-1-Based therapeutics. \nLearn more: https://ter.li/b0yt9f
URL:http://www.pharmajournalist.com/event/2nd-glp-1-based-therapeutics-summit/
LOCATION:Wyndham Boston Beacon Hill\, 5 Blossom St\, Boston\, MA\, 02114\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T094043
CREATED:20250116T114600Z
LAST-MODIFIED:20250116T114600Z
UID:40301-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:3rd mRNA Process Development & Manufacturing Summit Europe
DESCRIPTION:The 3rd mRNA Process Development & Manufacturing Summit 2025 returns as Europe’s premier industry-focused forum\, dedicated to optimizing process development for mRNA therapeutics and vaccines. This event will address end-to-end process optimisation\, regulatory compliance to streamline approvals\, while also advancing scalable and cost-efficient manufacturing solutions\, to support drug developers in delivering safer and more effective mRNA drugs to patients faster. \nBringing together leading experts from CEPI\, Merck\, CureVac\, BioNTech\, Altamira\, Genevation\, and more\, this summit will showcase cutting-edge advancements in end-to-end process development and manufacturing to support the production of high-quality\, cost-effective mRNA therapeutics at scale. \nDownload the event guide for full details: https://ter.li/4omn9n
URL:http://www.pharmajournalist.com/event/3rd-mrna-process-development-manufacturing-summit-europe/
LOCATION:Hotel Palace Berlin\, Germany
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250506
DTEND;VALUE=DATE:20250509
DTSTAMP:20260515T094043
CREATED:20250220T124530Z
LAST-MODIFIED:20250220T124530Z
UID:40548-1746489600-1746748799@www.pharmajournalist.com
SUMMARY:2nd ADC Payload Summit
DESCRIPTION:The 2nd ADC Payload Summit (May 6-8 | Boston\, MA) is the first and only conference exclusively focusing on ADC payloads\, helping you to reimagine the medicinal chemistry of traditional cytotoxic payloads while scouting the next generation of ADC payload innovations. \n \nWith novel payload categories such as degraders\, RNA polymerase II inhibitors\, immunomodulators\, gene silences\, and splice modulators entering the clinic\, don’t miss this opportunity to meet with fellow peers to explore the benefits of these diverse mechanisms of action to develop the next blockbuster ADC. \nThis event will also feature cutting-edge data presentations from emerging players in the field\, including Lycia Therapeutics and Heidelberg Pharma\, showcasing their latest advancements in payload technologies and clinical trial outcomes. With 80+ professionals from across the ADC landscape in attendance\, the summit offers ample networking opportunities to foster collaboration\, exchange ideas\, and drive the future of ADC therapy forward. \nOver three days of deep discussions and collaborative sessions\, attendees will gain practical insights into optimizing payload efficacy\, improving structure-activity relationships\, and exploring the latest payload classes entering the clinic. \nHere are some of the agenda highlights you cannot afford to miss: \n– Gain insights from Eisai on “Engineering STING/TLR Agonist Payloads to Amplify Anti-Tumor Immune Responses Without Triggering Cytokine Induction” exploring the therapeutic niche and potential of STING agonist payloads. \n– Join Takeda in “Navigating the Evolution of ADC Payloads – From Topo1 Success to Future Innovation” to discuss why Topo1 inhibitors dominated the clinic so fast\, what other modes of action and payload classes need to do to match that clinical success\, and where there is whitespace for novel payloads to gain ground in a competitive ADC landscape. \n– Hear from Merck on “Accelerating Degrader-Antibody Conjugate Design Through Strategic Integration of Traditional ADC & Expertise in TPD” to learn about translating physicochemical property optimization strategies from traditional ADCs to address unique degrader payload solubility and stability challenges. \nDon’t miss this opportunity to connect with the ADC community and shape the future of payload design. Join us in Boston for this exclusive event and be at the forefront of ADC innovation. \nTo know more visit: https://ter.li/j0dvm6
URL:http://www.pharmajournalist.com/event/2nd-adc-payload-summit/
LOCATION:Hilton Boston Back Bay\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250512
DTEND;VALUE=DATE:20250515
DTSTAMP:20260515T094043
CREATED:20250225T112204Z
LAST-MODIFIED:20250225T112204Z
UID:40566-1747008000-1747267199@www.pharmajournalist.com
SUMMARY:4th ALS Drug Development Summit
DESCRIPTION:The ALS Drug Development Summit is the definitive industry-led forum dedicated to advancing breakthroughs in ALS therapeutics. With the field evolving rapidly\, recent milestones—such as Insitro’s AI-driven target discovery with Bristol Myers Squibb and Dewpoint Therapeutics’ collaboration with Mitsubishi Tanabe Pharma America on TDP-43 condensate modulators—highlight the momentum in novel drug discovery. Meanwhile\, QurAlis’ clinical trials for QRL-101 and QRL-201 and innovations in biomarker platforms are reshaping the treatment landscape. \nJoin 200+ scientific leaders in Boston to tackle key challenges in target validation\, biomarker development\, and clinical trial optimization—driving progress toward effective ALS and FTD therapies. \nTo know more visit: https://ter.li/48rlwg
URL:http://www.pharmajournalist.com/event/4th-als-drug-development-summit/
LOCATION:Revere\, 200 Stuart St\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250513
DTEND;VALUE=DATE:20250516
DTSTAMP:20260515T094043
CREATED:20250214T120932Z
LAST-MODIFIED:20250214T120932Z
UID:40492-1747094400-1747353599@www.pharmajournalist.com
SUMMARY:3rd Precision Medicine in Inflammatory Bowel Disease Summit
DESCRIPTION:Following a year of exceptional progress in IBD drug development\, fierce competition in clinical trials for Chron’s Disease and Ulcerative Colitis remains high\, and it’s time for biopharma to push the boundaries of efficacy and distinguish their therapies amongst the market. \nFeaturing three days of data-driven sessions from 25+ world-class speakers\, the 3rd Precision Medicine in Inflammatory Bowel Disease returns as the field’s most comprehensive learning and networking forum; dedicated to showcasing the latest data and advances in IBD therapeutic development. \nSee the full program here: https://ter.li/tjjok6 \nWith transformative advancements in disease understanding\, AI-powered biomarker development\, patient stratification\, and advanced monitoring techniques paving the way for a new era of precision IBD therapies\, join 80+ IBD specialists to: \n\nRefine models and proof-of-concept studies to reduce clinical trial failure rates and improve translational outcomes\nInnovate treatment pathways to optimize safety and efficacy\nMinimize adverse events while enhancing therapeutic synergies\nLeverage emerging therapeutic modalities to refine patient selection and optimize therapeutic outcomes\n\nWhen & Where: May 13-15\, 2025 | Boston\, MA \nWho: 80+ Precision Medicine\, Diagnostics\, Translational\, Clinical\, Computational Biology\, Gastrointestinal and Inflammation experts \nAgenda: https://ter.li/tjjok6
URL:http://www.pharmajournalist.com/event/3rd-precision-medicine-in-inflammatory-bowel-disease-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250519
DTEND;VALUE=DATE:20250521
DTSTAMP:20260515T094043
CREATED:20250402T111945Z
LAST-MODIFIED:20250402T111945Z
UID:40815-1747612800-1747785599@www.pharmajournalist.com
SUMMARY:TPD & Induced Proximity Pharma Partnering Summit
DESCRIPTION:From molecular glue discovery to the development of degrader-antibody conjugates\, pharma is transforming through strategic transactions and by leveraging protein degradation technologies to expand target discovery and drug previously ‘undruggable’ targets. \nThis provides biotech with the opportunity to understand pharma’s targets of interest and the options for increased specificity and selectivity compared to traditional molecules. \nJoin the TPD & Induced Proximity Pharma Partnering Summit to accelerate partnership interest in your protein degradation pipeline or platform\, by hearing first-hand: \n\nWhat: What are pharma’s targets of interest\, and what data is sparking or prohibiting deal-making across TPD?\nWho: Who is the right person at each pharma\, specifically for induced proximity assets?\nHow: How are pharma analyzing data for a research collaboration versus a licensing deal?\n\nVIEW THE FULL EVENT GUIDE \nSecure your place here or get in touch with the team – info@hansonwade.com
URL:http://www.pharmajournalist.com/event/tpd-induced-proximity-pharma-partnering-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:General Enquiries: info@hansonwade.com or Partnership Enquiries: sponsor@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250520
DTEND;VALUE=DATE:20250523
DTSTAMP:20260515T094043
CREATED:20250225T113954Z
LAST-MODIFIED:20250225T113954Z
UID:40583-1747699200-1747958399@www.pharmajournalist.com
SUMMARY:4th GPCRs-Targeted Drug Discovery Summit
DESCRIPTION:The 4th GPCR-Targeted Drug Discovery Summit: Transforming the Discovery of Novel GPCR-Targeted Therapies. \nWith positive clinical read outs by Tectonic Therapeutics and recent funding rounds for Confo Therapeutics & Septerna\, the potential for novel GPCR drug classes to treat a plethora of diseases grows. Now more than ever\, there is a need for the community to come together to share scientific advancements and collaboration opportunities across the full spectrum of GPCR drugs\, from small molecules to therapeutic proteins and antibodies. \nThe 4th GPCRs-Targeted Drug Discovery Summit is returning to Boston to showcase the hottest targets of interest\, mechanism of action of new GPCR ligands\, cutting-edge computational tools to identify high-potential candidates\, and effective translational strategies to drive forward discovery & development pipelines to patients in need.\n\nFind out everything you need to know about the Summit here: https://ter.li/2c54a7
URL:http://www.pharmajournalist.com/event/4th-gpcrs-targeted-drug-discovery-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250520
DTEND;VALUE=DATE:20250523
DTSTAMP:20260515T094043
CREATED:20250422T121846Z
LAST-MODIFIED:20250422T122446Z
UID:40956-1747699200-1747958399@www.pharmajournalist.com
SUMMARY:6th Gene Therapy Analytical Development Summit Europe
DESCRIPTION:The 6th Gene Therapy Analytical Development Summit Europe is the leading platform for advancing gene therapy analytics\, from IND/IMPD filings to clinical trials and regulatory approvals. As the field moves toward late-stage development\, gain industry-focused insights tailored for Europe. \nJoin 24+ experts to tackle characterisation\, stability\, contamination risks\, and comparability across vectors and diseases. Network with biotech\, pharma\, MHRA\, and British Pharmacopoeia to share solutions and shape the future of gene therapy. \nDon’t miss the chance to explore analytical precision\, QC strategy\, and the delivery of safe\, effective therapies! \nTo know more visit: https://ter.li/w8deua
URL:http://www.pharmajournalist.com/event/6th-gene-therapy-analytical-development-summit-europe/
LOCATION:Novotel London West\, 1 Shortlands\, Hammersmith\, London\, W6 8DR\, United Kingdom
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T094043
CREATED:20250307T113641Z
LAST-MODIFIED:20250307T113641Z
UID:40683-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:3rd Retinal Imaging Biomarkers & Endpoints Summit
DESCRIPTION:The 3rd Retinal Imaging Biomarkers & Endpoints Summit will bring together leading experts spanning medical directors\, researchers\, clinical\, and imaging scientists from more than 30 organizations spearheading ophthalmic development with deep learning systems and sophisticated AI imaging technologies. It’s here they will explore the latest advancements in retinal imaging\, biomarkers\, and endpoints for ophthalmic drug development. \nThis highly anticipated meeting will delve into the evolving landscape of retinal diseases\, offering in-depth discussions on innovative imaging techniques\, biomarker discovery\, and the critical role of endpoints in clinical trials. Attendees will have the opportunity to engage with top-tier scientists\, researchers\, and industry leaders who will be presenting cutting-edge research\, techniques\, and case studies\, providing you with hyper-relevant insights to accelerate your ophthalmic development. \nTopics will cover a range of retinal conditions\, including dry and wet AMD\, GA\, GR\, and DME\, focusing on the identification and validation of biomarkers that are vital for diagnosis\, prognosis\, and treatment response assessment. This meeting is the perfect bridge for those developing and using novel technologies to ensure the efficacious development of endpoints for regulatory approval. \nAttendees will benefit from interactive workshops\, panel discussions\, and case studies\, providing practical insights into the real-world challenges and opportunities in retinal disease research. Plus\, with 8+ hours of dedicated networking sessions designed to ensure attendees get to meet everyone in the room\, it’s a fantastic opportunity to build valuable connections and strengthen collaboration which will aid in fostering partnerships that will drive the future of retinal imaging and treatment outcomes. \nAnd with sessions being delivered by Alexion\, Opus Genetics\, Inflammx\, Bausch + Lomb\, REGENXBIO\, and many more you won’t want to miss this! \nWhether you’re a researcher\, drug developer\, clinician or solution provider\, the 3rd Retinal Imaging Biomarkers & Endpoints Summit promises to be a pivotal point in the calendar for those involved in the development of therapies for retinal diseases. \nJoin us to be at the forefront of this rapidly advancing field and contribute to the next wave of innovations in retinal health… \nView the event guide for more information: https://ter.li/hcmzr0 \nSecure your pass: https://ter.li/tq8jmz
URL:http://www.pharmajournalist.com/event/3rd-retinal-imaging-biomarkers-endpoints-summit/
LOCATION:Hilton Boston Logan Airport\, One Hotel Dr\, Boston\, MA\, 02128\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250527
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T094043
CREATED:20250416T103747Z
LAST-MODIFIED:20250416T103747Z
UID:40951-1748304000-1748563199@www.pharmajournalist.com
SUMMARY:2nd Cell & Gene Therapy Pricing & Reimbursement Summit
DESCRIPTION:Current limitations across pricing\, coverage\, and payment frameworks are lasering out and hindering global access to many approved cell and gene therapies (CGTs). The Cell & Gene Therapy Pricing & Reimbursement Summit is here to change that. \nReturning for its 2nd edition\, this unique summit will share real-world case studies of success and setback in ensuring patients can access CGTs to spearhead reform in this thorny landscape. \nIndustry-led discussions will center on innovative payment models being developed and applied\, new stop-loss and reinsurance programs\, and how leading companies are ensuring coverage and uptake of their commercialized therapies. You’ll also leave with actionable learnings from recent CMS policy changes\, including the Access Model\, Medicaid Drug Rebate Program Final Rule\, and proposed increases to inpatient CAR-T reimbursement rates. \nJoin leading biopharma\, government agencies\, commercial payers\, academics\, and market access-specialist service providers – to align on the current market access strategy and policy challenges hindering widespread adoption of these ground-breaking therapies\, enhance your payer coverage and improve patient access. \nTo know more visit: https://ter.li/0g5eq9
URL:http://www.pharmajournalist.com/event/2nd-cell-gene-therapy-pricing-reimbursement-summit/
LOCATION:Marriott Washington Capitol Hill\, 175 L Street NE\, WA\, 20002\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T094043
CREATED:20250217T143826Z
LAST-MODIFIED:20250217T143826Z
UID:40519-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:4th Circular & Self-Amplifying RNA Therapeutics Summit
DESCRIPTION:Join the 4th Circular & Self-Amplifying RNA Therapeutics Summit! \nUnleashing the Next Generation of RNAs for Widespread Therapeutic Applications \nWith CSL Seqirus and Arcturus Therapeutics successfully developing the first approved self-amplifying RNA vaccine\, the field of next generation RNAs celebrates the potential of circular and self-amplifying RNAs to provide improved stability\, durability\, longevity and efficacy for treating a wide array of diseases. \nThis May\, the 4th Circular & Self-Amplifying RNA Therapeutics Summit (previously known as ‘Next Generation RNA Therapeutics Summit) is landing back in Boston\, as the unique opportunity to unite with leading stakeholders in the next generation RNA field\, including the likes of Sail Biomedicines\, Merck\, Novo Nordisk\, Replicate Bioscience and more. This is your one-stop shop to hear the latest approaches and applications of circular and self-amplifying RNA therapeutics and vaccines and gain actionable insights for fast-tracking your RNA programs toward the clinic. \nJoin 80+ RNA experts navigating through challenges such as RNA design\, delivery\, purity\, and manufacturing to accelerate high-quality and scalable next-generation RNA therapeutics and vaccines towards approval and the patients in need. \nTo know more visit: https://ter.li/lemzh2
URL:http://www.pharmajournalist.com/event/4th-circular-self-amplifying-rna-therapeutics-summit/
LOCATION:The Colonnade Hotel\, 120 Huntington Ave\, Boston\, MA\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250528
DTEND;VALUE=DATE:20250530
DTSTAMP:20260515T094043
CREATED:20250219T115152Z
LAST-MODIFIED:20250219T115152Z
UID:40525-1748390400-1748563199@www.pharmajournalist.com
SUMMARY:3rd Gene Therapy Potency Assay Summit
DESCRIPTION:Accelerating the Route to Commercialization with Robust Potency Assay Development \nFollowing a challenging year in the gene therapy field\, the 3rd Gene Therapy Potency Assay Summit returns at a crucial time when drug developers increasingly recognize that a robust potency assay is fundamental to both clinical success and commercial viability. As regulatory expectations continue to evolve\, it has never been more important to develop assays that are accurate\, reproducible\, and aligned with regulatory standards. \nWhile many industry meetings touch on potency in a broad or non-technical manner\, this summit stands apart as the only event fully dedicated to the complexities of potency assay development. With an emphasis on deep technical discussions\, attendees will gain unparalleled insights into phase-appropriate assay development\, methodology advancements\, reducing lot-to-lot variability\, and meeting evolving regulatory expectations. By bringing together a specialized community of Analytical Development\, Quality Control\, and Regulatory experts\, this meeting offers a unique platform to discuss challenges\, share strategies\, and explore innovative solutions. \nOne of the key highlights of this year’s agenda is the session “Navigating Regulatory Requirements for Gene Therapy Potency Assays”\, presented by Melody Dai\, Vice President\, Head of Regulatory Affairs & CMC at Novasenta. This session\, taking place at 9:00 AM on Day 1\, will provide an in-depth exploration of regulatory strategies for potency assays\, covering both early and ongoing regulatory engagement. Attendees will learn how to build effective relationships with regulatory agencies\, navigate evolving requirements\, and prepare for critical regulatory meetings and submissions. By leveraging insights from experts with hands-on experience in clinical-stage gene therapy products\, this session will offer practical guidance that extends beyond theoretical discussions. \nWith a carefully curated agenda and contributions from industry leaders\, the 3rd Gene Therapy Potency Assay Summit provides an essential opportunity to advance potency assay strategies\, enhance regulatory preparedness\, and accelerate the path to commercialization. Whether you are refining your assay methodologies\, tackling regulatory complexities\, or preparing for the next phase of development\, this event will equip you with the expertise and connections needed to drive success in gene therapy. \nFind Out More Now!
URL:http://www.pharmajournalist.com/event/3rd-gene-therapy-potency-assay-summit/
LOCATION:Revere Hotel Boston Common\, 200 Stuart Street\, Boston\, 02116\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
END:VCALENDAR